PharmaVault
گنجینه اطلاعات داروسازی
The Pharmaceutical Information Vault
Excipient monograph · مونوگراف ماده جانبی
pharmavault.ir
Simethicone
سایمتیکون
1Nonproprietary names
- BPSimeticone
- Ph. Eur.Simeticone
- USP–NFSimethicone
2Synonyms and trade names
Activated dimethicone; activated polymethylsiloxane; simeticone; dimethicone with silicon dioxide; silicone antifoam
3Chemical name and CAS Registry Number
Mixture of fully methylated linear siloxane polymers (dimethicone) with finely divided silicon dioxide · [8050-81-5]
4Empirical formula and molecular weight
[–(CH3)2SiO–]n with SiO2
5Functional category
Semi-solid base, emollient
Typical concentrations: — · Dosage forms: Liquid, Solid
6Applications in pharmaceutical formulation
Simethicone is used as an antifoaming agent: as an active ingredient in antiflatulent products, and as a processing aid to suppress foaming during the manufacture of liquids, emulsions and fermentation products. It is also used in topical barrier preparations and as a defoamer in oral suspensions. It is effective at low concentrations, usually well below 1% of the product, often supplied as an aqueous emulsion for ease of dispersion.
7Description
A translucent, grey, viscous fluid. Pharmacopoeial material contains about 90.5–99.0% polydimethylsiloxane and 4.0–7.0% silicon dioxide; the silica particles are hydrophobised by the silicone, which makes the mixture a much more effective defoamer than dimethicone alone.
8Typical properties
- Silicon dioxide content
- 4.0–7.0%
- Defoaming activity
- foam collapses within 15 seconds in the pharmacopoeial test
- Solubility
- practically insoluble in water and ethanol; the polysiloxane fraction is soluble in toluene, chloroform and ether, leaving the silica as a residue
- Appearance
- grey, translucent, viscous liquid
9Stability and storage conditions
Chemically stable and resistant to oxidation. Simethicone emulsions may separate if frozen or exposed to high temperatures. Store in a well-closed container.
10Incompatibilities
Few incompatibilities have been reported. Silicone antifoams can be deactivated by strong emulsifiers and surfactants, and may interfere with the wetting of tablet surfaces in film coating.
11Method of manufacture
Prepared by dispersing finely divided silicon dioxide (silica) in dimethicone and treating the mixture, usually with heat, so that the silica surface becomes coated with the silicone. Dimethicone itself is made by hydrolysis and polycondensation of dichlorodimethylsilane with chlorotrimethylsilane as a chain stopper.
12Safety
Simethicone is physiologically inert, is not absorbed from the gastrointestinal tract and is regarded as non-toxic and non-irritant. It is given orally in relatively large doses as an antiflatulent without significant adverse effects.
13Handling precautions
Observe normal precautions for the quantity handled. Spills are very slippery and should be cleaned up promptly; eye protection is recommended.
14Regulatory status
Included in the FDA Inactive Ingredient Database (oral preparations) and in non-parenteral medicines licensed in Europe. Simethicone is also an FDA monograph active ingredient for over-the-counter antiflatulent products.
15Related substances
Dimethicone; cyclomethicone; colloidal silicon dioxide.
16Comments
When used as a processing antifoam, add the minimum amount needed, since excess silicone can cause oily films, turbidity or poor adhesion of later coating layers. Pre-dilution or use of an emulsion grade helps uniform dispersion in aqueous systems.